We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+20.21%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.06B
AUM Growth
-$300M
Cap. Flow
-$581M
Cap. Flow %
-28.26%
Top 10 Hldgs %
86.31%
Holding
41
New
11
Increased
3
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
TRAX
First Tracks Biotherapeutics
TRAX
+$59.3M
2
FULC icon
Fulcrum Therapeutics
FULC
+$39.8M
3
CGON icon
CG Oncology
CGON
+$25.6M
4
LEGN icon
Legend Biotech
LEGN
+$21.6M
5
STOK icon
Stoke Therapeutics
STOK
+$20.4M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$323M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$238M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$156M
4
XNCR icon
Xencor
XNCR
+$26.3M
5
RLAY icon
Relay Therapeutics
RLAY
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.95%
2 Miscellaneous 1.95%
3 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
1
Zymeworks
ZYME
$2.02B
$600M 29.19%
22,970,388
– –
ANAB icon
2
AnaptysBio
ANAB
$1.67B
$532M 25.86%
7,880,094
– –
AKTS
3
Aktis Oncology
AKTS
$1.43B
$155M 7.56%
4,824,469
– –
CGON icon
4
CG Oncology
CGON
$6.59B
$106M 5.16%
1,494,300
+392,300
+36% +$25.6M
ETON icon
5
Eton Pharmaceutcials
ETON
$1.71B
$78.6M 3.82%
2,171,938
– –
CRSP icon
6
CRISPR Therapeutics
CRSP
$5.58B
$75.8M 3.68%
1,389,276
– –
ORIC icon
7
Oric Pharmaceuticals
ORIC
$1.37B
$72.9M 3.54%
6,728,116
– –
TRAX
8
First Tracks Biotherapeutics
TRAX
$1.5B
$63.9M 3.11%
+3,174,519
New +$59.3M
LKFT
9
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$50M 2.43%
1,667,119
– –
NGNE icon
10
Neurogene
NGNE
$732M
$40M 1.94%
1,271,342
– –
CGON icon
11
CALL
CG Oncology
CGON
$6.59B
$39.9M 1.94%
+561,500
New +$36.7M
STOK icon
12
Stoke Therapeutics
STOK
$2.04B
$24M 1.17%
735,000
+635,000
+635% +$20.4M
FULC icon
13
Fulcrum Therapeutics
FULC
$294M
$24M 1.17%
+6,549,866
New +$39.8M
LEGN icon
14
Legend Biotech
LEGN
$3.87B
$23.1M 1.12%
+800,000
New +$21.6M
BBOT
15
BridgeBio Oncology
BBOT
$701M
$21.5M 1.05%
2,823,126
– –
MBX
16
MBX Biosciences
MBX
$3.03B
$21.4M 1.04%
388,500
-388,500
-50% -$13.6M
ZBIO
17
Zenas BioPharma
ZBIO
$2.04B
$20M 0.97%
789,500
– –
ATRA icon
18
Atara Biotherapeutics
ATRA
$92.3M
$17.8M 0.87%
1,552,000
+1,452,407
+1,458% +$11.6M
RLAY icon
19
Relay Therapeutics
RLAY
$4.11B
$13.1M 0.63%
697,948
-1,206,814
-63% -$17.5M
AURA icon
20
Aura Biosciences
AURA
$767M
$11.8M 0.58%
+1,666,667
New +$11.9M
ODTX
21
Odyssey Therapeutics
ODTX
$1.17B
$10.4M 0.51%
+555,555
New +$9.74M
EIKN
22
Eikon Therapeutics
EIKN
$595M
$9.56M 0.46%
732,606
– –
PHVS icon
23
Pharvaris
PHVS
$2.48B
$8.13M 0.4%
+235,000
New +$7.11M
ZURA icon
24
Zura Bio
ZURA
$548M
$6.96M 0.34%
1,179,715
– –
PHAT icon
25
Phathom Pharmaceuticals
PHAT
$743M
$6.78M 0.33%
625,000
– –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2026 Portfolio in Review

As of Q2 2026, EcoR1 Capital held 41 positions worth $2.06B, down 13% from $2.36B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

EcoR1 Capital withdrew a net $581M in Q2 2026, closing 8 positions and reducing 4 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $323M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, EcoR1 Capital opened a new position in First Tracks Biotherapeutics worth $63.9M.

  • EcoR1 Capital's largest Q2 2026 buy was First Tracks Biotherapeutics: 3,174,519 shares worth $63.9M.
  • EcoR1 Capital added most to CG Oncology in Q2 2026, an estimated $25.6M increase.
  • EcoR1 Capital's biggest Q2 2026 reduction was Relay Therapeutics, cutting an estimated $17.5M.
  • EcoR1 Capital fully exited Jazz Pharmaceuticals in Q2 2026, selling an estimated $323M.
  • EcoR1 Capital's ten largest holdings make up 86% of its $2.06B portfolio in Q2 2026.
  • EcoR1 Capital opened 11 new positions and closed 8 in Q2 2026.
  • EcoR1 Capital's portfolio value fell 13% quarter-over-quarter to $2.06B.

Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.